Table 6.
Clinical Trial Numbers | Title | Status | Targets | Tumor Types | Phases | Start Date | End Date |
---|---|---|---|---|---|---|---|
NCT01723813 | Peptide Vaccinations Plus GM-CT-01 in Melanoma | Terminated | Galectins + Vaccine | Metastatic Melanoma | Phase 1 Phase 2 |
April 2012 | April 2015 |
NCT04139902 | PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) | Not yet recruiting | TIM-3 + PD-1 | Melanoma | Phase 2 | 15 March 2020 | 15 December 2024 |
NCT03708328 | A Dose Escalation and Expansion Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants with Advanced and/or Metastatic Solid Tumors | Recruiting | TIM-3 + PD-1 | Solid Tumors | Phase 1 | 15 October 2018 | 13 September 2022 |
NCT02575404 | GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients | Recruiting | Galectins (esp. Gal-3) + PD-1 | Various | Phase 1 | 16 May 2016 | October 2021 |
NCT02117362 | Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients with Metastatic Melanoma | Completed | Galectins (esp. Gal-3) + PD-1 | Metastatic Melanoma | Phase 1 | 8 May 2014 | 28 November 2018 |